The Protected Graft Copolymer (PGC™) is a carrier with a "backbone" of poly-amino acids and multiple "shields" that protect the active drug. The drug molecule can be bound to the PGC backbone by covalent binding (with chemical modification of the drug) however, the use of reversible binding (PRB) to load a drug to the carrier is most often the most advantageous (and accomplished often without any active agent modification). Delivery of drugs via the PGC nano-carrier can increase bloodstream circulation time and enable site-specific delivery, enhancing efficacy and patient convenience. The PGC drug carrier can also decrease the side effects of toxic drugs.

Intellectual Property Protection
Three U.S. patents have been issued to Harvard/Mass General with respect to the core PGC nanotechnology. PharmaIN was granted an exclusive worldwide license to this patented platform technology in the Company's field of use by Massachusetts General Hospital in 2001. PharmaIN is also pursuing its own patents for the PRB platform and specific PGC and PRB applications. The Company has one US patent issued to date, US Number 7,138,105 (see Jan. 4, 2007 Press Release ) and several other US and international patent applications at the prosecution stage.